Business Description
Scinai Immunotherapeutics Ltd
ISIN : US09073Q1058
Share Class Description:
FRA:2F5: ADRTotal Employee Number:
31Description
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.85 | |||||
Equity-to-Asset | 0.67 | |||||
Debt-to-Equity | 0.3 | |||||
Debt-to-EBITDA | -0.91 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -9.49 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 53.4 | |||||
3-Year FCF Growth Rate | 60.7 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 43.86 | |||||
9-Day RSI | 40.6 | |||||
14-Day RSI | 38.3 | |||||
3-1 Month Momentum % | -61.27 | |||||
6-1 Month Momentum % | -63.85 | |||||
12-1 Month Momentum % | -86.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.35 | |||||
Quick Ratio | 1.35 | |||||
Cash Ratio | 1.1 | |||||
Days Sales Outstanding | 65.15 | |||||
Days Payable | 68.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -141.2 | |||||
Shareholder Yield % | 323.92 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -386.98 | |||||
Operating Margin % | -689.65 | |||||
Net Margin % | 147.93 | |||||
EBITDA Margin % | -570.41 | |||||
FCF Margin % | -443.59 | |||||
OCF Margin % | -442.56 | |||||
ROE % | 10.82 | |||||
ROA % | 7.31 | |||||
ROIC % | -39.79 | |||||
3-Year ROIIC % | -113.96 | |||||
ROC (Joel Greenblatt) % | -41.28 | |||||
ROCE % | -40.35 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Price-to-Owner-Earnings | 0.38 | |||||
PS Ratio | 0.83 | |||||
PB Ratio | 0.13 | |||||
Price-to-Tangible-Book | 0.13 | |||||
EV-to-EBIT | -1.58 | |||||
EV-to-EBITDA | -1.91 | |||||
EV-to-Revenue | 10.87 | |||||
EV-to-FCF | -2.45 | |||||
Earnings Yield (Greenblatt) % | -63.29 | |||||
FCF Yield % | -251.98 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Scinai Immunotherapeutics Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.585 | ||
| EPS (TTM) (€) | -1.951 | ||
| Beta | 2.7122 | ||
| 3-Year Sharpe Ratio | -0.71 | ||
| 3-Year Sortino Ratio | -1.04 | ||
| Volatility % | 107.36 | ||
| 14-Day RSI | 38.3 | ||
| 14-Day ATR (€) | 0.011482 | ||
| 20-Day SMA (€) | 0.216 | ||
| 12-1 Month Momentum % | -86.81 | ||
| 52-Week Range (€) | 0.202 - 2.28 | ||
| Shares Outstanding (Mil) | 5.17 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Scinai Immunotherapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Scinai Immunotherapeutics Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-22 11:00 | In 150 days | ||
| Third quarter earnings results for 2026 | 2026-12-02 | In 129 days | ||
| Second quarter earnings results for 2026 | 2026-09-02 | In 38 days | ||
| First quarter earnings results for 2026 | 2026-06-10 | 0.30 (-6.75%) | ||
| Annual report for 2025 | 2026-04-01 | 0.47 (-1.27%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-01 | 0.47 (-1.27%) | ||
| General meeting for 2025 | 2025-12-22 11:00 | 0.60 (-1.64%) | ||
| Third quarter earnings results for 2025 | 2025-12-02 | 0.87 (+6.75%) | ||
| Second quarter earnings results for 2025 | 2025-09-02 | 2.28 (+0.00%) | ||
| First quarter earnings results for 2025 | 2025-05-30 | 2.32 (-2.52%) |
Show
Entries
Scinai Immunotherapeutics Ltd Frequently Asked Questions
What is Scinai Immunotherapeutics Ltd(FRA:2F5)'s stock price today?
The current price of FRA:2F5 is €0.21. The 52 week high of FRA:2F5 is €2.28 and 52 week low is €0.20.
When is next earnings date of Scinai Immunotherapeutics Ltd(FRA:2F5)?
The next earnings date of Scinai Immunotherapeutics Ltd(FRA:2F5) is 2026-09-02 Est..
Does Scinai Immunotherapeutics Ltd(FRA:2F5) pay dividends? If so, how much?
Scinai Immunotherapeutics Ltd(FRA:2F5) does not pay dividend.
Press Release
Articles on Scinai Immunotherapeutics Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers